Delaney Dennis R increased its position in Novartis AG (NYSE:NVS) by 1.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,650 shares of the company’s stock after buying an additional 295 shares during the period. Novartis AG makes up about 3.0% of Delaney Dennis R’s portfolio, making the stock its 13th largest position. Delaney Dennis R’s holdings in Novartis AG were worth $1,473,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Smith Salley & Associates raised its position in shares of Novartis AG by 3.0% in the second quarter. Smith Salley & Associates now owns 36,090 shares of the company’s stock worth $3,012,000 after buying an additional 1,067 shares during the last quarter. Puzo Michael J raised its position in shares of Novartis AG by 0.7% in the second quarter. Puzo Michael J now owns 72,525 shares of the company’s stock worth $6,054,000 after buying an additional 475 shares during the last quarter. Somerville Kurt F raised its position in shares of Novartis AG by 1.5% in the second quarter. Somerville Kurt F now owns 194,189 shares of the company’s stock worth $16,210,000 after buying an additional 2,960 shares during the last quarter. Boston Advisors LLC bought a new position in shares of Novartis AG during the second quarter worth approximately $215,000. Finally, Greenleaf Trust raised its position in shares of Novartis AG by 9.7% in the second quarter. Greenleaf Trust now owns 11,143 shares of the company’s stock worth $930,000 after buying an additional 987 shares during the last quarter. 11.27% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Novartis AG (NYSE NVS) traded up 0.22% during midday trading on Friday, reaching $83.36. 920,198 shares of the company’s stock were exchanged. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The stock has a market cap of $195.30 billion, a PE ratio of 30.43 and a beta of 0.73. The stock’s 50 day moving average is $84.25 and its 200-day moving average is $78.58.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The business had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. During the same quarter in the previous year, the business posted $1.23 earnings per share. The business’s revenue was down 1.8% compared to the same quarter last year. On average, equities analysts expect that Novartis AG will post $4.73 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/novartis-ag-nvs-shares-bought-by-delaney-dennis-r/1473410.html.

Several research firms recently commented on NVS. BidaskClub lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Friday. Cowen and Company set a $90.00 target price on shares of Novartis AG and gave the company a “hold” rating in a report on Wednesday. Morgan Stanley raised shares of Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Monday, July 17th. Finally, Zacks Investment Research lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. Novartis AG has a consensus rating of “Hold” and a consensus target price of $83.56.

In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.01% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.